Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531192 | 0.91 | TERT (0.51) | TERTDRD4HDAC1SSTR3 | |
| SCHEMBL4025247 | 0.85 | TERT (0.67) | TERTNR1H4 | |
| SCHEMBL6786405 | 0.84 | TERT (0.66) | TERTDRD4 | |
| SCHEMBL4020343 | 0.84 | TERT (0.68) | TERTNR1H4 | |
| SCHEMBL6785800 | 0.83 | TERT (0.73) | TERTNR1H4 | |
| SCHEMBL6786925 | 0.83 | TERT (0.64) | TERTDRD4 | |
| SCHEMBL6786598 | 0.82 | TERT (0.66) | TERTDRD4 | |
| SCHEMBL4195176 | 0.81 | TERT (0.67) | TERTDRD4 | |
| SCHEMBL4021678 | 0.81 | TERT (0.69) | TERTNR1H4 | |
| SCHEMBL6791574 | 0.80 | TERT (0.68) | TERTDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492547-B2 | E.G., TRANS-3-NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-5-DIMETHYLAMINOMETHYL-PHENYL)-AMIDE; ANTITUMOR, ANTICARCINOGENIC AGENTS; TELOMERASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | claimed |
| US-20020128495-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-12 | — | — | US | claimed |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | disclosed |
| WO-2009100323-A2 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
| US-6492547-B2 | E.G., TRANS-3-NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-5-DIMETHYLAMINOMETHYL-PHENYL)-AMIDE; ANTITUMOR, ANTICARCINOGENIC AGENTS; TELOMERASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020128495-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-12 | — | — | US | disclosed |
| WO-2002051795-A1 | CARBOXAMIDES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE AND PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | NAAA, ELANE, APEH | TERT 1053/4885DRD4 4373/4885HDAC1 1270/4885 |
| US-20020128495-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | ASS1, ADCY1, SUCNR1 | TERT 4716/4885DRD4 2515/4885HDAC1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.